On Tuesday, Protara Therapeutics Inc (NASDAQ: TARA) opened lower -5.01% from the last session, before settling in for the closing price of $5.39. Price fluctuations for TARA have ranged from $2.77 to $7.82 over the past 52 weeks.
During the last 5-year period, the sales growth of Healthcare Sector giant was 55.31%. Company’s average yearly earnings per share was noted 40.17% at the time writing. With a float of $46.17 million, this company’s outstanding shares have now reached $51.63 million.
Protara Therapeutics Inc (TARA) Breakdown of a Key Holders of the stock
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Protara Therapeutics Inc is 10.58%, while institutional ownership is 46.08%. The most recent insider transaction that took place on May 14 ’25, was worth 63,800. In this transaction Director of this company bought 20,000 shares at a rate of $3.19, taking the stock ownership to the 51,000 shares. Before that another transaction happened on Mar 26 ’25, when Company’s Chf Scientific Operations Off sold 21,224 for $4.53, making the entire transaction worth $96,145. This insider now owns 98,861 shares in total.
Protara Therapeutics Inc (TARA) Recent Fiscal highlights
If we go through the results of last quarter, which was made public on 12/31/2024, the company posted -0.43 earnings per share (EPS) for the quarter, besting the agreed prediction (set at -0.56) by 0.13. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.36 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 40.17% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 10.56% during the next five years compared to 55.31% growth over the previous five years of trading.
Protara Therapeutics Inc (NASDAQ: TARA) Trading Performance Indicators
Check out the current performance indicators for Protara Therapeutics Inc (TARA). In the past quarter, the stock posted a quick ratio of 13.69.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.44, a number that is poised to hit -0.35 in the next quarter and is forecasted to reach -1.39 in one year’s time.
Technical Analysis of Protara Therapeutics Inc (TARA)
Looking closely at Protara Therapeutics Inc (NASDAQ: TARA), its last 5-days average volume was 0.8 million, which is a drop from its year-to-date volume of 0.99 million. As of the previous 9 days, the stock’s Stochastic %D was 34.85%.
During the past 100 days, Protara Therapeutics Inc’s (TARA) raw stochastic average was set at 44.33%, which indicates a significant increase from 11.69% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.27 in the past 14 days, which was lower than the 0.34 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $5.67, while its 200-day Moving Average is $4.12. However, in the short run, Protara Therapeutics Inc’s stock first resistance to watch stands at $5.38. Second resistance stands at $5.64. The third major resistance level sits at $5.82. If the price goes on to break the first support level at $4.95, it is likely to go to the next support level at $4.77. Now, if the price goes above the second support level, the third support stands at $4.51.
Protara Therapeutics Inc (NASDAQ: TARA) Key Stats
There are currently 51,631K shares outstanding in the company with a market cap of 264.35 million. Presently, the company’s annual sales total 0 K according to its annual income of -44,600 K. Last quarter, the company’s sales amounted to 0 K and its income totaled -13,260 K.
